Advanced Search

 

Study ID Status Title Patient Level Data
FAS40008_1 Completed An interventional three year study for asthma control - In what way and in what kind of population is it possible toget asthmatic patients free from symptoms, keep the patients in work, restore a normal lung function, diminish hyperreactivity and normalise quality of life?
FAS40009 Completed The therapeutic ratio of inhaled corticosteroids in adult asthma: A dose-range comparison between fluticasone propionate and budesonide measuring their effect on bronchial hyperresponsiveness and adrenal cortex function.
FAS40012 Completed Early Intervention with Inhaled Corticosteroids in Wheezing Pre-school Children: A Single-Centre, Double-Blind, Randomised 5 Years Parallel-Group Study Comparing Adjusted Dosing of Inhaled Fluticasone Propionate With Inhaled Placebo Both Administered by Metered Dose Inhaler via a Babyhaler. Study Listed on ClinicalStudyDataRequest.com
FAS40017 Completed A double blind, randomised, parallel group study with Flixotide Diskus (250microg) bd and Pulmicort Turbohaler (400microg) bd to compare lowest effective maintenance doses followed by an open health economic evaluation.
FAS40019 Completed A single centre study, randomised, double blind, double-dummy crossover study to determine if the total lung deposition of FP is affected by delivery system (pMDI with Babyhaler or Volumatic compared with the Diskus inhaler), in children aged between 4-6 years and 12-15 years old with asthma.
FBX104114 Completed A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects with Hepatic Fibrosis who Have Failed Prior Antiviral Therapy
FCO30002 Completed A double/blind, randomised, controlled, three parallel group, multicenter study to compare the acute effects of inhaled Flixotide/Salmeterol vs. Decortin/Flixotide/Salmeterol vs. Salmeterol in patients with COPD
FCO40004 Completed Self-management of COPD, including self-treatment of exacerbations in an outpatient population.
FFA10001 Completed A randomised, double-blind, placebo-controlled, dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GW685698X in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
FFA10002 Completed A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability and systemic pharmacokinetics and pharmacodynamics of repeat doses (500, 1000 and 2000mg) of GW685698X administered once daily for fourteen da Study Listed on ClinicalStudyDataRequest.com
FFA10003 Completed A part-randomised, single dose, open label, 6-way cross-over study to assess the relative systemic pharmacokinetics and absolute bioavailability of GW685698X and FP (1000mg) administered via Diskhaler® in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
FFA10007 Completed A randomised, double-blind, placebo-controlled, 5-way cross incomplete block design study to investigate the relative potency of single inhaled doses of GW685698X (3µm material) and fluticasone propionate (FP) on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge in mild asthmatic patients Study Listed on ClinicalStudyDataRequest.com
FFA10008 Completed A randomised, single dose, open label, 3-way cross-over study to assess the systemic pharmacokinetics of GW685698X (1000mg) administered via Diskhaler with or without charcoal and an intravenous dose (250mg) in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
FFA10009 Completed A randomised, double-blind, placebo-controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability and PK of once daily inhaled GW685698 with the excipient COA administered via DISKUS in healthy subjects Study Listed on ClinicalStudyDataRequest.com
FFA10013 Completed A study to investigate the pharmacokinetics of a single inhaled dose (400mcg) of GW685698X and its effect on serum cortisol in patients with impaired liver function and matched control subjects. Study Listed on ClinicalStudyDataRequest.com
FFA10022 Completed A randomised, double-blind, placebo-controlled, incomplete block, 3-way cross-over study to investigate the effect of repeat inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) in mild asthmatic patients Study Listed on ClinicalStudyDataRequest.com
FFA10026 Completed A randomised, double-blind, placebo-controlled, six-way cross design study to investigate the effect of single inhaled doses of NCE and fluticasone propionate on airway responsiveness to adenosine 5’-monophosphate challenge in mild asthmatic patients. Study Listed on ClinicalStudyDataRequest.com
FFA10027 Completed A randomised, double-blind, placebo-controlled, 6-way cross-over design study to investigate the effect of 250 µg single inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge in mild asthmatic patients Study Listed on ClinicalStudyDataRequest.com
FFA10028 Completed A randomised, double-blind, placebo-controlled, balanced incomplete block, multiple dose crossover study to investigate the effect of 3 Days repeat dosing of GW685698X and fluticasone propionate (1000 µg) on exhaled nitric oxide in mild to moderate asthmatic patients. Study Listed on ClinicalStudyDataRequest.com
FFA106783 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200 mcg Twice Daily, GW685698X 200 mcg and 400 mcg Once Daily in the Morning, and GW685698X 200 mcg and 400 mcg Once Daily in the Evening Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (12 years of age and older) with Persistent Asthma Study Listed on ClinicalStudyDataRequest.com
FFA109684 Completed A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent an Study Listed on ClinicalStudyDataRequest.com
FFA109685 Completed A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Low-Dose ICS Therapy Study Listed on ClinicalStudyDataRequest.com
FFA109687 Completed A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Administered Once Daily and Fluticasone Propionate Inhalation Powder 100mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy Study Listed on ClinicalStudyDataRequest.com
FFA20001 Completed A randomised, double-blind, double dummy, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GW685698X 100mcg administered once daily either in the morning or the evening and GW685698X 250mcg administered once daily in the evening all administered by inhalation via DISKHALER for 28 days in subjects with persistent bronchial asthma. Study Listed on ClinicalStudyDataRequest.com
FFR100010 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis (SAR) Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.